LONDON, UK, 12 March 2015, 07.00 GMT – Norgine and Arc Medical Design Ltd. today announced a partnership that will see Norgine commercialising and distributing ENDOCUFF VISION™, a Class 1 sterile medical device used in colonoscopy, across a number of major European markets, Australia and New Zealand. Norgine’s first launch of ENDOCUFF VISION™ will take place in the UK Q2 2015.
ENDOCUFF VISION™ is a single use, sterile endoscopic overtube, which fits onto the distal end of most endoscopes, and has been designed to improve tip control during extubation and enhance mucosal vision in patients with diseases of the colon, including colorectal cancer. The improved visualisation of lesions has been shown to result in an increase in both the Adenoma Detection Rate (ADR) and Mean Adenomas per Patient (MAP) rate., , , 
Colorectal cancer is the second most common cause of cancer-related mortality in the world; nearly 1.4 million new cases of colorectal cancer were diagnosed worldwide in 2012 and 412,000 people are diagnosed with it every year in Europe.,  The detection and removal of adenomas during colonoscopy substantially reduces both the development of and death from colorectal cancer. In the UK alone, diagnosis at the earliest stage is associated with a 93.2% five-year survival rate, compared with a 6.6% five-year survival rate for diagnosis of metastatic colorectal cancer.
Peter Stein, Chief Executive Officer Norgine, commented, “We are excited about our new partnership with Arc Medical and the promotion of ENDOCUFF VISION™, a device which not only leads to a significant increase in lesion detection, but also ensures a quality colonoscopy and avoids the need for repeat procedures – thus significantly improving the patient experience. This partnership is a further example of Norgine’s commitment to improving quality in colonoscopy and adds to our existing bowel cleansing portfolio.”
“We are delighted to work in partnership with Norgine to expand the number of markets where ENDOCUFF VISION™ is available,” said Tas Javed, Managing Director, Arc Medical. “We strive to turn innovative ideas into successful products that fill an unmet need in medical design, ultimately improving health outcomes and patient quality of life.”
Notes to Editors
About ENDOCUFF VISIONTM
ENDOCUFF VISION™ is a single-use endoscopic overtube, which fits onto the distal end of an endoscope. The size of the device is approximately 2.5cm long by 1.5cm wide (3.5cm with arms extended), and is of minimal weight.
ENDOCUFF VISION™ has unique hinged arms that lie flat against the shaft of the endoscope to create a smooth, low friction surface during intubation. During extubation the arms of the device flare out to stabilise the tip of the endoscope and centre it in the lumen, providing greater control and enabling the physician to flatten the folds of the colon, leading to superior visualisation.
The device is manufactured in the UK by Boddingtons Plastics Limited, a plastics manufacturer, which currently holds the CE mark for the product.
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth. Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France. For more information, please visit www.norgine.com. In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE™ and the sail logo are trademarks of the Norgine group of companies.
ENDOCUFF VISION™ is a registered trademark of Arc Medical Design Ltd.
About Arc Medical Design Ltd.
Providing award-winning and innovative products worldwide, Arc Medical are leading the way in increasing Adenoma Detection Rates (ADR) and improving retrieval methods.
As a clinician driven company, Arc Medical is uniquely positioned to understand the needs of those working in the gastro-intestinal sector and strives to improve physician experience and patient outcome.
Charlotte Andrews: Mob: +44 (0)7714 061485
Isabelle Jouin: Mob: +44 (0)7714 406372
Arc Medical Design Ltd:
Tas Javed: Tel: +44 (0)113 242 0131
 Biecker E, et al. Novel Endocuff-assisted colonoscopy significantly increases the polyp detection rate. A randomized controlled trial. J Clin Gastroenterol. 2014;00:000-000
 Floer M, et al. Higher adenoma detection rate with Endocuff assisted colonoscopy. Plos One. 3 December 2014; 10.1371
 Lenze F, et al. Endocuff-assisted colonoscopy: a new accessory to improve adenoma detection rate? Technical aspects and first clinical experiences. Endoscopy. 2014; 46(7):610-614
 Marsano J, et al. Endocuff assisted colonoscopy increases adenoma detection rate: A multicentre study. ASGE Posters, 10095, DDW, Chicago 2014
 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-1403
 Colorectal Cancer Statistics, World Cancer Research Fund International, http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics [Accessed 4 March 2015]
 Zavoral M et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009;15(47):5907-5915
 LeClercq CMC, Bouwens MWE, Rondagh, EJA et al. Postcolonoscopy colorectal cancers are preventable: a population-based study. Gut 2014;63:957-963
 National Cancer Intelligence Network. Colorectal Cancer Survival by Stage. NCIN Data Briefing, June 2009